

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): May 14, 2021

Rain Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-40356
(Commission
File Number)

81-1130967
(IRS Employer
Identification No.)

8000 Jarvis Avenue, Suite 204
Newark, CA 94560
(Address of Principal Executive Offices)

(510) 953-5559
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	RAIN	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of President

On May 14, 2021, the Board of Directors (the “Board”) of Rain Therapeutics Inc. (the “Company”) approved the recommendation of Avanish Vellanki, the Company’s Chief Executive Officer and Chairman of the Board, to appoint Robert Doebele, M.D., Ph.D. to the position of President, effective as of such date. Dr. Doebele will continue to serve as the Company’s Chief Scientific Officer. Mr. Vellanki, who previously held the title of President, ceased serving as President upon Dr. Doebele’s appointment.

CEO Compensation

On May 14, 2021, the Board also approved the recommendations of the Compensation Committee of the Board of a 2021 annual base salary and 2021 bonus target for Mr. Vellanki of \$562,200 and 50%, respectively. The salary change is retroactive to April 26, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 20, 2021

Rain Therapeutics Inc.

By: /s/ Avanish Vellanki

Avanish Vellanki

Chairman and Chief Executive Officer